Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

daclizumab

- PMLiVE

Karuna’s shares spike on schizophrenia drug data

Value leaps to more than $1bn following mid-stage trial results

- PMLiVE

Biogen under fire over $88,000 Vumerity annual price

Pricing pressure levelled at Tecfidera follow-up MS drug

- PMLiVE

Merck acquires pre-clinical biotech Calporta for up to $576m

Expands into early-stage neurodegeneration research field

- PMLiVE

Otsuka presses on with Alzheimer’s agitation drug

Surprise announcement comes on the heels of phase 3 trial fail

Roche Basel Switzerland

Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA

Will file for approval in US and other world markets before end of the year

- PMLiVE

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Will pay $100m upfont and pledges $210m in milestone payments

- PMLiVE

China okays Green Valley’s algae-based drug for Alzheimer’s drug

Due to start phase 3 trials in the US and Europe next year

- PMLiVE

Germany’s Vivoryon raises €43m for Alzheimer’s drug trial

Results of European study expected in 2022

- PMLiVE

Biogen and Eisai revive abandoned aducanumab in shock turnaround

Companies plan to file the deserted Alzheimer’s drug with FDA

- PMLiVE

Biogen’s R&D chief Ehlers heads for the exit

Follows multiple late-stage Alzheimer's study failures

- PMLiVE

Avanir’s week goes from bad to worse with Alzheimer’s stumble

Suffers a blow as second phase 3 trial misses the mark

- PMLiVE

Darwinian leadership in the life sciences industry

Good leadership is about adapting to the exceptional features of our industry

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links